Medigen Vaccine Biologics Corporation (TPEX:6547)

Taiwan · Delayed Price · Currency is TWD

59.80

-1.00 (-1.64%)

Sep 24, 2026, 1:30 PM CST

Market Cap	19.66B +55.1%
Revenue (ttm)	573.85M -9.2%
Net Income	-166.77M
EPS	-0.51
Shares Out	328.75M
PE Ratio	n/a
Forward PE	65.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,524,901
Open	60.90
Previous Close	60.80
Day's Range	59.50 - 61.20
52-Week Range	33.50 - 72.20
Beta	0.00
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Medigen Vaccine Biologics

Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respirat... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2012

Employees 103

Stock Exchange Taipei Exchange

Ticker Symbol 6547

Full Company Profile

Financial Performance

In 2025, Medigen Vaccine Biologics's revenue was 613.17 million, an increase of 1.24% compared to the previous year's 605.64 million. Losses were -281.71 million, 250.1% more than in 2024.

Financial Statements